Passage BIO, Inc. (PASG): Entry into a Material Definitive Agreement

Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 tm2618476d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: PASSAGE BIO, INC.; PEREGRINE MERGER SUB, INC.; and REMIX THERAPEUTICS, INC. Dated as of June 24, 2026 TABLE OF CONTENTS Page Article I DEFINITIONS AND INTERPRETATIVE PROVISIONS 3 1.1

Event · M&A · definitive agreement
Role
acquirer
Counterparty
Remix Therapeutics, Inc.
Consideration
stock
Expected close
fourth quarter of 2026
Also in this documentOffering · $100M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Jun 24, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PASG
Bullish
medium confidence
Mentioned
$PASG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PASGBullishMed
01

Why it matters

This is a fresh, primary disclosure of a material definitive merger agreement, which typically changes deal probability, expected valuation, and near-term trading behavior for the acquirer’s shares.

02

Market read

Fresh M&A agreement disclosure creates immediate re-pricing and sets up upcoming deal milestones (proxy/stockholder vote, regulatory approvals, closing conditions).

03

What to watch

Traders should watch for the proxy/registration statement timing, any termination fee/expense provisions, and how contingent value rights (CVR) are structured—these can materially affect valuation and spreads.

Relevance 6/10Novelty 7/10Timing: after-hours/filing today (8-K filed 2026-06-24 16:15 ET)

Background

The 8-K attaches an Agreement and Plan of Merger dated June 24, 2026, where Passage Bio (PASG) will merge its wholly owned subsidiary (Peregrine Merger Sub) into Remix Therapeutics, making Remix a wholly owned subsidiary of Passage.

Company-level read

Ticker impact

$PASGBullishMedium confidence
Context

Passage Bio entered a material definitive merger agreement with Peregrine Merger Sub and Remix Therapeutics, implying a change-of-control and issuance of PASG shares.

Expected impact

Likely positive bias for PASG on deal-readthrough, with volatility around deal terms, financing, and approval milestones.

Evidence & confidence

The filing is a primary-source disclosure of a merger agreement (Item 1.01) and includes board approvals/recommendations and merger mechanics, which typically drive immediate sentiment and trading activity.

Market effects

Signals continued consolidation in biotech; may modestly affect sentiment for small/mid-cap acquisition targets and deal financing expectations.

Primarily US small-cap biotech M&A sentiment; limited direct regional spillover beyond the involved names.

Low global macro relevance; mostly company-specific deal dynamics.

Counterpoint

Merger agreements often face termination risk (conditions, regulatory hurdles, financing), so initial enthusiasm can fade if key details (CVR terms, financing, approvals) disappoint.

Key entities

  • Passage Bio, Inc.

    US-listed acquirer entering a material definitive merger agreement (PASG).

  • Peregrine Merger Sub, Inc.

    Wholly owned merger subsidiary of Passage that will merge into Remix.

  • Remix Therapeutics, Inc.

    Target in the merger agreement; will become a wholly owned subsidiary of Passage upon closing.

Related articles

$PASGMed

Passage Bio Received Notice of Noncompliance

Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.

$PNFPMed

Pinnacle Bank, a wholly-owned subsidiary of Pinnacle Financial Partners, Inc., issued $600 million aggregate principal amount of its 7.200% Fixed-to-Floating…

Pinnacle Financial Partners, Inc. (PNFP) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 18, 2026, Pinnacle Bank (the “Bank”), a wholly-owned subsidiary of Pinnacle Financial Partners, Inc. (the “Company”), issued $600 million aggregate principal amount of its 7.200% Fixed-to-Floating Rate Subordinated Bank Notes due 2038 (the “Sub

$NXPIMed

NXP B.V., NXP Funding LLC, NXP USA, Inc. and NXP Semiconductors N.V. executed and delivered an underwriting agreement, by and among the Issuers, the Company…

NXP Semiconductors N.V. (NXPI) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 17, 2026, NXP B.V., NXP Funding LLC, NXP USA, Inc. (the “ Issuers ”) and NXP Semiconductors N.V. (the “ Company ”) executed and delivered an underwriting agreement (the “ Underwriting Agreement ”), by and among the Issuers, the Company and BNP

$DANMed

Dana Incorporated, a Delaware corporation, announced that it had commenced offers to purchase for cash any and all of the Company’s outstanding (i) 4.250%…

DANA Inc (DAN) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 6, 2026, Dana Incorporated, a Delaware corporation (the “Company”), announced that it had commenced offers to purchase for cash (collectively, the “Tender Offers”) any and all of the Company’s outstanding (i) 4.250% Senior Notes due 2030 (the